• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    How Investors May Respond To Nurix Therapeutics (NRIX) Deepening Losses And Sharply Lower Collaboration Revenue

    Simply Wall St·07/18/2026 14:17:04
    Listen to the news
    • Nurix Therapeutics, Inc. reported past second-quarter and six-month results to May 31, 2026, with revenue falling to US$9.04 million for the quarter and a net loss of US$89.54 million, and six-month revenue of US$15.30 million alongside a net loss of US$176.71 million.
    • The widening basic loss per share from continuing operations, rising to US$0.81 for the quarter and US$1.60 for the half year, highlights growing cost pressures relative to sharply lower collaboration and operating revenue.
    • Next, we examine how this sharp year-over-year revenue contraction and larger net loss shape Nurix Therapeutics’ investment narrative for investors.

    Uncover the next big thing with 20 elite penny stocks that balance risk and reward.

    What Is Nurix Therapeutics' Investment Narrative?

    For anyone considering Nurix Therapeutics today, the core belief still rests on its protein degradation platform eventually translating into commercially meaningful drugs, with the Roche partnership around NX‑5948 as the clearest near-term validation. The latest results, with sharply lower collaboration revenue and a much larger net loss, cut against that story in the short run by spotlighting how dependent the company has been on deal income while its pipeline matures. At the same time, the US$700 million Roche upfront and potential US$2.30 billion in milestones, announced just weeks before these earnings, remain the key catalyst, and the Q2 figures do not change that pending deal. The bigger near-term risk now is how Nurix balances rising R&D spend, deepening losses and past shareholder dilution before those partnership economics fully kick in.

    However, investors should be aware of how quickly ongoing losses might force fresh capital raising. Our valuation report unveils the possibility Nurix Therapeutics' shares may be trading at a premium.

    Exploring Other Perspectives

    NRIX 1-Year Stock Price Chart
    NRIX 1-Year Stock Price Chart
    The Simply Wall St Community’s single fair value estimate of US$32.50 sits against widening losses and heavy cash needs, prompting you to weigh Roche’s partnership upside against funding risk and execution on the clinical pipeline.

    Explore another fair value estimate on Nurix Therapeutics - why the stock might be worth just $32.50!

    Decide For Yourself

    Disagree with this assessment? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

    No Opportunity In Nurix Therapeutics?

    Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

    • Invest in the nuclear renaissance through our list of 90 elite nuclear energy infrastructure plays powering the global AI revolution.
    • Capitalize on the AI infrastructure supercycle with our selection of the 53 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
    • Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 29 best rare earth metal stocks of the very few that mine this essential strategic resource.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.